Zynerba Pharmaceuticals Inc (ZYNE.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2014||Chairman of the Board, Chief Executive Officer|
|53||2016||Chief Financial Officer, Vice President - Corporate Development|
|60||2014||Secretary, General Counsel and Vice President, Human Resources|
|2017||Vice President - Investor Relations and Corporate Communications|
- BRIEF-Zynerba Pharmaceuticals Reports Q1 Loss Of $0.91 Per Share
- BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study
- BRIEF-Zynerba Pharmaceuticals Appoints John P. Butler To Board Of Directors
- BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)
- BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60